Prospect News: News for Cancer Genetics, Inc.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with C > Issuers starting with C, PP only > All stories on Cancer Genetics, Inc. > Stories on Cancer Genetics, Inc., PP only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Cancer Genetics, Inc.

9/9/2016	PP	Cancer Genetics eyes $5.5 million registered direct offering of stock
5/20/2016	PP	Cancer Genetics aims to conduct $5 million offering of stock, warrants
11/6/2015	PP	Cancer Genetics prices $12 million public offering of stock at $4.00
10/30/2015	PP	Cancer Genetics plans to conduct public offering of its common shares
7/16/2015	PP	Cancer Genetics intends to conduct $20 million at-the-market offering
10/24/2013	PP	Cancer Genetics greenshoe fully exercised in $46.01 million stock sale
10/22/2013	PP	Cancer Genetics prices $40 million public offering of common stock
10/17/2013	PP	Cancer Genetics aims to price $50 million public offering of stock
10/17/2013	PP	Cancer Genetics to price $50 million public offering of stock Oct. 22
10/8/2013	PP	Cancer Genetics intends to price $46 million public offering of stock
9/5/2013	PP	Cancer Genetics greenshoe exercised for $16.05 million stock sale
8/14/2013	PP	Cancer Genetics prices $15 million public offering of stock at $10.00
8/5/2013	PP	Cancer Genetics picks co-manager Feltl for $15 million sale of stock
6/5/2013	PP	Cancer Genetics aims to price $15 million public offering of its stock
4/5/2013	PP	Cancer Genetics greenshoe exercise lifts IPO proceeds to $6.9 million
4/4/2013	PP	Cancer Genetics prices $6 million initial public stock sale at $10.00
1/4/2012	PP	Cancer Genetics to price initial public offering of its common stock

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.